Investment for new tech
Hearing Diagnostics raises funds for trials on device
Niki McKenzie: test should help retailers
Edinburgh company Hearing Diagnostics has received £715,000 from the Archangels investment syndicate to allow its testing system to undergo trials.
The trials will take place with universities and hearing aid retailers in the UK with a view to full market launch in 2021.
Colin Horne, co-founder and chief technology officer at the company, said the investment would enable the firm to realise a “paradigm-shifting new product”.
Niki McKenzie, joint managing director at Archangels, said: “Hearing loss is a condition that is experienced across the world and yet the technology around hearing tests has barely changed in recent years.
“Hearing Diagnostics appears to have invented a low cost, accurate and accessible test that will help hearing aid retailers to identify customers who need support with their hearing quickly and cost effectively.”
Charles Sweeney, formerly CEO of Bloxx and Document Outsourcing Group and a non-executive director of a number of tech businesses, will join Hearing Diagnostics as chairman.
Jacqui McLaughlin, CEO of Reactec, and Phil Harris, CEO of Vert Rotors, will join the board as non-executive directors.